Disease reduction in the presence of antagonists was evaluated by using two parameters: efficacy, as the percentage of mean disease reduction, and consistency, variability in the level of control provided, which derived from the standard deviation of the means. The efficacy-consistency ratio was called Biological Control Index (BCI) according to Byrne et al. (2005),